Search results for "remission"

showing 10 items of 213 documents

Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study

2020

Abstract Background The role of the gut microbiota in Crohn’s disease (CD) is established and fecal microbiota transplantation (FMT) is an attractive therapeutic strategy. No randomized controlled clinical trial results are available. We performed a randomized, single-blind, sham-controlled pilot trial of FMT in adults with colonic or ileo-colonic CD. Method Patients enrolled while in flare received oral corticosteroid. Once in clinical remission, patients were randomized to receive either FMT or sham transplantation during a colonoscopy. Corticosteroids were tapered and a second colonoscopy was performed at week 6. The primary endpoint was the implantation of the donor microbiota at week 6…

Microbiology (medical)AdultMaleCrohn’s diseasemedicine.medical_specialtymedicine.drug_class[SDV]Life Sciences [q-bio]ColonoscopyPilot ProjectsGut floraMicrobiologyGastroenterologySeverity of Illness Indexlcsh:Microbial ecologylaw.inventionFecal microbiota transplantation03 medical and health sciencesFeces0302 clinical medicineRandomized controlled trialCrohn DiseaselawAdrenal Cortex HormonesInternal medicinemedicineClinical endpointHumansSingle-Blind Method030304 developmental biology0303 health sciencesCrohn's diseasebiologymedicine.diagnostic_testMicrobiotaResearchRemission Inductionbiology.organism_classificationmedicine.disease3. Good healthClinical trialTransplantationCrohn's diseaseTreatment OutcomeResearch DesignRandomized controlled trialCorticosteroidlcsh:QR100-130030211 gastroenterology & hepatologyFemaleMicrobiome
researchProduct

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (R…

2015

Background: VEGF and VEGF receptor-2-mediated angiogenesis contribute to hepatocellular carcinoma pathogenesis. Ramucirumab is a recombinant IgG1 monoclonal antibody and VEGF receptor-2 antagonist. We aimed to assess the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma following first-line therapy with sorafenib. Methods: In this randomised, placebo-controlled, double-blind, multicentre, phase 3 trial (REACH), patients were enrolled from 154 centres in 27 countries. Eligible patients were aged 18 years or older, had hepatocellular carcinoma with Barcelona Clinic Liver Cancer stage C disease or stage B disease that was refractory or not amenable to locoregional therapy…

MaleTime FactorsKaplan-Meier EstimateGastroenterologyLiver diseaseClinical endpoint610 Medicine & healthramucirumab sorafenib HCCAged 80 and overeducation.field_of_studyLiver NeoplasmsRemission InductionAntibodies MonoclonalMiddle AgedSorafenibTreatment OutcomeOncologyLiver NeoplasmHepatocellular carcinomaFemaleSurvival AnalysiHumanmedicine.drugAdultNiacinamidePhenylurea CompoundSorafenibmedicine.medical_specialtyCarcinoma HepatocellularTime FactorPopulationAntibodies Monoclonal HumanizedPlaceboDisease-Free SurvivalDrug Administration ScheduleFollow-Up StudieRamucirumabDouble-Blind MethodInternal medicineConfidence IntervalsmedicineCarcinomaHumanseducationProportional Hazards ModelsAgedDose-Response Relationship Drugbusiness.industryPhenylurea CompoundsPatient Selectionmedicine.diseaseSurvival Analysisdigestive system diseasesSurgeryProportional Hazards ModelbusinessConfidence IntervalFollow-Up StudiesThe Lancet Oncology
researchProduct

Substance use, medication adherence and outcome one year following a first episode of psychosis

2016

Both substance use and poor medication adherence are associated with poor outcome in psychosis. To clarify the contributions of substance use and poor medication adherence to poor outcome in the year following a first episode of psychosis, 205 patients were evaluated for use of tobacco, alcohol, cannabis and stimulants at their psychosis onset, and in a 1-year follow-up. Data on medication adherence and symptom remission were also collected. Patients had high rates of overall substance use before (37-65%) and after psychosis onset (45-66%). 44% showed poor medication adherence and 55% did not reach remission from psychosis. Nicotine dependence and cannabis use after psychosis onset signific…

Nicotine dependenceAdultMalePsychosismedicine.medical_specialtyFirst episode psychosisRemissionSubstance-Related DisordersMedication adherenceSubstance useCannabis useMedication AdherenceCannabis use; First episode psychosis; Medication adherence; Nicotine dependence; Remission; Substance use; Acute Disease03 medical and health sciencesYoung Adult0302 clinical medicineSettore M-PSI/08 - Psicologia ClinicamedicineHumansYoung adultCannabis use; First episode psychosis; Medication adherence; Nicotine dependence; Remission; Substance use; Acute Disease; Adult; Antipsychotic Agents; Female; Follow-Up Studies; Humans; Male; Medication Adherence; Middle Aged; Psychotic Disorders; Substance-Related Disorders; Treatment Outcome; Young AdultNicotine dependencePsychiatryMedication adherenceSettore MED/25 - PsichiatriaBiological PsychiatryFirst episodebiologyCannabis useMiddle Agedmedicine.diseasebiology.organism_classificationFirst episode psychosi030227 psychiatryTreatment OutcomePsychotic DisordersPsychiatry and Mental HealthAcute DiseaseFemaleCannabisSubstance usePsychology030217 neurology & neurosurgeryAntipsychotic AgentsFollow-Up Studies
researchProduct

Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells.

1999

Abstract Circulating plasma cells in 10 cases of reactive plasmacytosis had a shared phenotype with early plasma cell (CD19+CD38+ CD138+ CD40+CD45+ CD11a+ CD49e−CD56−). In most cases, a minor subpopulation of CD28+ plasma cells was also detected. Reactive plasma cells were highly proliferative, suggesting the presence of circulating progenitors (plasmablasts). After CD138+ plasma cell removal, highly proliferative CD138− plasmablasts differentiated into CD138+ plasma cells within a few days. This differentiation, which was associated with increased CD38 and decreased HLA-DR expression, was further confirmed by a large increase in intracellular Ig content (associated with Ig secretion) and w…

MaleCellular differentiationRemission SpontaneousApoptosisCD38Plasma cellBiochemistry0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesChildCells Cultured[INFO.INFO-BI] Computer Science [cs]/Bioinformatics [q-bio.QM]0303 health sciencesbiologyAntibodies MonoclonalCell DifferentiationHematologyMiddle Agedmedicine.anatomical_structureFemaleAntibodyMultiple MyelomaAdultPlasma CellsImmunologyLymphocytosisCD19ImmunophenotypingImmunoglobulin kappa-Chains03 medical and health sciencesImmunoglobulin lambda-ChainsAntigens CD[ INFO.INFO-BI ] Computer Science [cs]/Bioinformatics [q-bio.QM]medicineHumansProgenitor cellAgedRetrospective Studies030304 developmental biologyCD40Interleukin-6PlasmacytosisCell Biologymedicine.diseaseHematopoietic Stem CellsMolecular biologyReceptors Interleukin-6Immunologybiology.protein[INFO.INFO-BI]Computer Science [cs]/Bioinformatics [q-bio.QM]030215 immunology
researchProduct

Measurements of the volume and density of intracerebral tumors by CT following therapy.

1982

For the interpretation of curative measures in patients with cerebral tumors CT is of increasing importance. The therapeutic effects can be demonstrated by close follow-up studies without any of the disadvantage of invasive neuroradiological methods. Our investigations of 125 patients with cerebral tumors are based on volume and density determinations. The CT studies of removed or inoperable tumors followed by radiation and/or cytostatic therapy prove that the best results follow a combination of both. In the present cases however, if CT proves postoperatively, at the end of radiation or at the beginning of the application of cytostatics that there is a residual mass, a complete remission c…

medicine.medical_specialtyNeurologyAstrocytomamedicineHumansRadiology Nuclear Medicine and imagingResidual massIn patientNeuroradiologybusiness.industryBrain NeoplasmsTherapeutic effectComplete remissionGliomaSurgeryEpendymomaCt techniqueNeurology (clinical)NeurosurgeryRadiologyCardiology and Cardiovascular MedicinebusinessGlioblastomaTomography X-Ray ComputedPinealomaMedulloblastomaNeuroradiology
researchProduct

HLA-DRB1*1301 AND *1302 protect against chronic hepatitis B

1997

Abstract Background/Aims: The outcome of acute hepatitis B infection may be influenced by host factors like the major histocompatibility complex (MHC). We have investigated MHC class I and class II antigens in patients with chronic hepatitis B compared to a healthy control population. To confirm the findings of this first study we performed a second study in a group of subjects who had spontaneously recovered from acute hepatitis B infection. Methods: Frequencies of MHC class I and class II antigens were analyzed in patients with chronic hepatitis B virus infection and in control subjects. MHC class I typing was done by standard microlymphocytotoxicity assays. DRB1 and DQA1 genotypes were d…

AdultHepatitis B virusRemission SpontaneousPopulationEnzyme-Linked Immunosorbent AssayMajor histocompatibility complexmedicine.disease_causePolymerase Chain ReactionHLA-DQ alpha-ChainsVirusHLA-DQ AntigensMHC class ImedicineHumansSerologic TestsProspective StudiesHepatitis B AntibodieseducationHLA-DRB1AllelesHepatitis B viruseducation.field_of_studyMHC class IIHepatitis B Surface AntigensHepatologybiologyHLA-DR AntigensHepatitis BVirologyChronic infectionImmunoglobulin GChronic DiseaseDNA ViralImmunologybiology.proteinHLA-DRB1 ChainsJournal of Hepatology
researchProduct

Effect of priming ith granulocyte-colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia

2003

BACKGROUND: Sensitization of leukemic cells with hematopoietic growth factors may enhance the cytotoxicity of chemotherapy in acute myeloid leukemia (AML). METHODS: In a multicenter randomized trial, we assigned patients (age range, 18 to 60 years) with newly diagnosed AML to receive cytarabine plus idarubicin (cycle 1) and cytarabine plus amsacrin (cycle 2) with granulocyte colony-stimulating factor (G-CSF) (321 patients) or without G-CSF (319). G-CSF was given concurrently with chemotherapy only. Idarubicin and amsacrin were given at the end of a cycle to allow the cell-cycle-dependent cytotoxicity of cytarabine in the context of G-CSF to have a greater effect. The effect of G-CSF on dise…

AdultMaleOncologymedicine.medical_specialtyAcute myeloblastic leukemiamedicine.medical_treatmentDisease-Free SurvivalRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorHumansMedicineIdarubicinSurvival analysisChemotherapybusiness.industryRemission InductionCytarabineInduction chemotherapyGeneral MedicineLeukemia Myelocytic AcuteMiddle Agedmedicine.diseaseSurvival AnalysisHematopoietic Stem Cell MobilizationGranulocyte colony-stimulating factorSurgeryLeukemia Myeloid AcuteLeukemiaCytarabineFemaleIdarubicinbusinessmedicine.drugNew England Journal of Medicine
researchProduct

Experimental Hepatitis

1994

Publisher Summary This chapter presents the animal models of experimental hepatitis (EAH). EAH was developed as a model of human autoimmune hepatitis (AIH). AIH in humans is a heterogeneous disease, which most often occurs in young females and generally responds very well to immunosuppressive therapy. AIH is often not recognized or is misdiagnosed as chronic non-A, non-B (non-C) viral hepatitis. Even when left untreated for considerable time periods, the disease in some patients is moderate to mild, and transient spontaneous remissions can be observed. EAH in many ways reflects this disease process. EAH also is often mild to moderate, and spontaneous remission occurs. Autoantibodies are cri…

PathogenesisHepatitisbusiness.industryImmunologyAutoantibodyMedicineIn patientSpontaneous remissionDiseaseAutoimmune hepatitisbusinessmedicine.diseaseViral hepatitis
researchProduct

ANCA-associated vasculitides: Recommendations of the French Vasculitis Study Group on the use of immunosuppressants and biotherapies for remission in…

2019

Treatment of vasculitides associated with anti-neutrophil cytoplasm antibodies (ANCA) (AAVs) has evolved dramatically in recent years, particularly since the demonstration of rituximab efficacy as remission induction and maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. In 2013, the French Vasculitis Study Group (FVSG) published recommendations for its use by clinicians. Since then, new data have made it possible to better specify and codify prescription of rituximab to treat AAVs. Herein, the FVSG Recommendations Committee, an expert panel comprised of physicians with extensive experience in the treatment and management of vasculitides, presents its con…

medicine.medical_specialtyCardiologyAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisMaintenance Chemotherapy03 medical and health sciencesRemission induction0302 clinical medicineMaintenance therapymedicineHumans030212 general & internal medicineMedical prescriptionIntensive care medicineSocieties Medical030203 arthritis & rheumatologybusiness.industryRemission InductionGranulomatosis with PolyangiitisGeneral Medicinemedicine.diseaseBiological TherapyPractice Guidelines as TopicRituximabFranceGranulomatosis with polyangiitisbusinessMicroscopic polyangiitisVasculitisMepolizumabImmunosuppressive Agentsmedicine.drugLa Presse Médicale
researchProduct

The "Honeymoon Phase" in Children with Type 1 Diabetes Mellitus (T1DM): Frequency, Duration and Predictive Factors at Onset

2012

Abstract: Aim of thè study was: to analyze thè epidemiological features of paediatric T1DM at onset and their relation to remission frequency and duration in thè first year of disease, to assess clinical effìcacy of Glucose Evaluation Trial REMission (GETREM) protocol in terms of induction and maintenance of thè "honeymoon phase" and to evaluate Insulin Dose-Adjusted A1C values at onset [IDAA1C = HbAlc% + (Insulin U/Kg/die x 4)] as a predictor of remission. 181 patients less than 15 years of age were admitted at our Department for T1DM onset and were treated according to GETREM protocol in thè years 2008-2011. The following data were recorded at onset: age, sex, modality of onset according …

Settore MED/38 - Pediatria Generale E SpecialisticaGlucose Evaluation Trial REMission HbA1c honeymoon phase
researchProduct